We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Graft Polymer (uk) Plc | LSE:GPL | London | Ordinary Share | GB00BMD1Z199 | ORD GBP0.001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.005 | 2.44% | 0.21 | 0.20 | 0.22 | 0.21 | 0.205 | 0.205 | 9,900,763 | 08:21:12 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 587k | -3.12M | -0.0014 | -1.50 | 4.71M |
12 August 2024
Graft Polymer (UK) Plc
("Graft Polymer" or the "Company")
Director resignation
Graft Polymer (UK) Plc (LON: GPL), an innovative biopolymer drug delivery systems development company, announces the resignation, with immediate effect, of Yifat Steuer from its board of directors and from the role of Chief Financial Officer.
Orana Corporate LLP will continue to provide support in relation to the Company's financial function whilst the Company proceeds to select a new CFO.
Nicholas Nelson, Chairman, commented:
"Yifat departs us with our sincere thanks for all she has done during the transitionary period since I became Chairman. She has provided us with invaluable guidance and professionalism.
"New board appointments are planned to steer the Company as it pursues its mission to innovate in drug delivery solutions. "
Enquiries:
Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director
Email: anthonytennyson@graftpolymer.co.uk
Allenby Capital (Broker)
Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)
+44 (0) 20 3328 5656
About Graft Polymer (UK) Plc
Graft Polymer plc ("Graft Polymer") (LON: GPL) is an innovative biopolymer drug delivery systems development company dedicated to enabling biopharmaceutical companies to enhance the effectiveness of their therapeutics. Our proprietary platform, a bioabsorbable self-nanoemulsifying drug delivery system (SNEDDS), represents a cutting-edge solution in drug delivery technology. By integrating active pharmaceutical ingredients (APIs) into our novel, patented delivery systems, we enable clients to improve the pharmacokinetics, bioavailability, and stability of their therapeutics.
For more information, please visit www.graftpolymer.co.uk.
1 Year Graft Polymer (uk) Chart |
1 Month Graft Polymer (uk) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions